Get started
Author

Enric Monreal

Observed names: E. Monreal, ENRIC MONREAL, Monreal, Enric
Observed institutions: Medical University of Lublin, Universitat Autònoma de Barcelona, Innsbruck Medical University, University of Basel, Universidad de Alcalá, Universität Innsbruck, Instituto de Salud Carlos III, Hospital Universitari Arnau de Vilanova, University Hospital of Basel, Spanish Multiple Sclerosis Network, University Hospital Münster, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario de La Princesa, Hospital Universitario de Fuenlabrada, Hospital Universitario Virgen de la Arrixaca, Hospital Universitario Ramón y Cajal, University of Birmingham
ORCID: 0000-0003-3293-0125
Observed ORCID: 0000-0003-3293-0125
OpenAlex ID: A5047180263
Acute‐onset smell and taste disorders in the context of COVID‐19: a pilot multicentre polymerase chain reaction based case–control study
2020 · Á. Beltrán‐Corbellini, J. L. Chico‐García, et al. · European Journal of Neurology · 363
PDF
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
2021 · José I. Fernández-Velasco, Jens Kuhle, et al. · Neurology Neuroimmunology & Neuroinflammation · 68
PDF
High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study
2020 · Enric Monreal, Susana Sainz de la Maza, et al. · European Journal of Clinical Microbiology & Infectious Diseases · 58
PDF
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis
2024 · Enric Monreal, José Ignacio Fernández-Velasco, et al. · Brain · 51
PDF
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs
2023 · Enric Monreal, José Ignacio Fernández-Velasco, et al. · JAMA Neurology · 51
Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome
2021 · Enric Monreal, Susana Sainz de la Maza, et al. · Neurology Neuroimmunology & Neuroinflammation · 40
PDF
Risk and outcomes of COVID‐19 in patients with multiple sclerosis
2021 · Irene Moreno‐Torres, Virginia Meca Lallana, et al. · European Journal of Neurology · 35
PDF
COVID-19 in Parkinson’s disease: what holds the key?
2020 · R. Sainz-Amo, B. Baena-Álvarez, et al. · Journal of Neurology · 33
PDF
Factors associated with dimethyl fumarate-induced lymphopenia
2019 · Susana Sainz de la Maza, Silvia Medina, et al. · Journal of the Neurological Sciences · 29
Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis
2021 · Carmen Picón, Amalia Tejeda-Velarde, et al. · Frontiers in Immunology · 28
PDF
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome
2025 · Nicolás Fissolo, Sabine Schaedelin, et al. · JAMA Neurology · 27
PDF
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis
2023 · Nicolás Fissolo, Pascal Benkert, et al. · Journal of Neurology Neurosurgery & Psychiatry · 26
PDF
Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients
2019 · Silvia Medina, Susana Sainz de la Maza, et al. · Annals of Clinical and Translational Neurology · 25
PDF
The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19
2020 · for the COVID-HRC group, Enric Monreal, et al. · Journal of Clinical Immunology · 23
PDF
Establishing Normal Serum Values of Neurofilament Light Chains and Glial Fibrillary Acidic Protein Considering the Effects of Age and Other Demographic Factors in Healthy Adults
2024 · Alexander Rodero-Romero, Enric Monreal, et al. · International Journal of Molecular Sciences · 22
Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis
2023 · Enric Monreal, José Ignacio Fernández-Velasco, et al. · Frontiers in Immunology · 17
PDF
The effect of timing of high-efficacy therapy on processing speed performance in multiple sclerosis
2022 · Andrés Labiano-Fontcuberta, Lucienne Costa-Frossard, et al. · Multiple Sclerosis and Related Disorders · 16
Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study
2024 · Lucienne Costa-Frossard França, Virginia Meca Lallana, et al. · CNS Drugs · 15
PDF
Contribution of Blood Biomarkers to Multiple Sclerosis Diagnosis
2025 · Manuel Comabella, Agustín Pappolla, et al. · Neurology Neuroimmunology & Neuroinflammation · 13
PDF
Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
2021 · Paulette Esperanza Walo-Delgado, Susana Sainz de la Maza, et al. · Scientific Reports · 13
PDF
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis
2024 · Manuel Comabella, Harald Hegen, et al. · Journal of Neurology · 12
PDF
Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients
2024 · Raquel Sainz-Amo, Alexander Rodero-Romero, et al. · International Journal of Molecular Sciences · 12
PDF
Non‐severe immunosuppression might be associated with a lower risk of moderate–severe acute respiratory distress syndrome in COVID‐19: A pilot study
2020 · Enric Monreal, Sainz de la Maza S, et al. · Journal of Medical Virology · 11
Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
2024 · Fernando Rodríguez-Jorge, José Ignacio Fernández-Velasco, et al. · Frontiers in Immunology · 10
Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis
2024 · Raquel Sainz-Amo, Alexander Rodero Romero, et al. · Frontiers in Immunology · 10
PDF
Works count: 85
Citation count: 1,146
H-index: 16
I10-index: 28
Year
Topic
Type